Milurit (Allopurinol)

Allopurinol, the active ingredient in Milurit, is a xanthine oxidase inhibitor presented as an oral dosage form for oral use. It lowers uric acid production and is used to manage gout, hyperuricemia, and to prevent tumor lysis syndrome in at‑risk patients.

GNH USA supplies Milurit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Milurit, a xanthine oxidase inhibitor, is employed in conditions where excess uric acid contributes to disease.

- Gout: lowers serum uric acid to prevent acute attacks and chronic joint damage. - Hyperuricemia: maintains uric acid within target range to reduce risk of crystal deposition. - Tumor lysis syndrome prevention: reduces uric acid surge during rapid tumor cell breakdown in oncology patients.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Rash or mild skin irritation. - Nausea or vomiting. - Diarrhea. - Abdominal discomfort. - Elevated liver enzymes.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Severe hypersensitivity reactions, including fever and organ involvement. - Bone marrow suppression or agranulocytosis. - Acute interstitial nephritis.

Before initiating Milurit, consider the following safety measures.

- Renal impairment: adjust dose and monitor renal function regularly. - Hepatic disease: use with caution and observe liver function tests. - History of hypersensitivity: discontinue immediately if rash or systemic symptoms develop. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Concomitant medications: review for potential interactions that may require dose adjustments. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Milurit can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Azathioprine: increased risk of bone marrow suppression. - Mercaptopurine: heightened toxicity due to impaired metabolism. - Warfarin: potentiation of anticoagulant effect, requiring close INR monitoring.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may diminish uric‑lowering efficacy. - ACE inhibitors: can enhance uric acid reduction, watch for over‑correction. - High‑dose vitamin C: may increase renal stone risk, monitor renal function.